Mercer Global Advisors Inc. ADV Decreases Position in Repligen Co. (NASDAQ:RGEN)

Mercer Global Advisors Inc. ADV lessened its holdings in Repligen Co. (NASDAQ:RGEN) by 5.9% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,679 shares of the biotechnology company’s stock after selling 168 shares during the quarter. Mercer Global Advisors Inc. ADV’s holdings in Repligen were worth $338,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently added to or reduced their stakes in the company. Norden Group LLC grew its holdings in Repligen by 1,711.6% in the 1st quarter. Norden Group LLC now owns 38,805 shares of the biotechnology company’s stock worth $7,137,000 after acquiring an additional 36,663 shares during the last quarter. Artemis Investment Management LLP grew its holdings in Repligen by 33.8% in the 1st quarter. Artemis Investment Management LLP now owns 167,813 shares of the biotechnology company’s stock worth $30,852,000 after acquiring an additional 42,380 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. grew its holdings in Repligen by 30.2% in the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 28,883 shares of the biotechnology company’s stock worth $5,312,000 after acquiring an additional 6,705 shares during the last quarter. Congress Asset Management Co. MA grew its holdings in Repligen by 14.6% in the 1st quarter. Congress Asset Management Co. MA now owns 88,013 shares of the biotechnology company’s stock worth $16,187,000 after acquiring an additional 11,213 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in Repligen by 21.7% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 335,836 shares of the biotechnology company’s stock worth $61,767,000 after acquiring an additional 59,903 shares during the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 0.8 %

RGEN opened at $145.93 on Monday. The company has a quick ratio of 5.56, a current ratio of 6.65 and a debt-to-equity ratio of 0.26. The firm has a 50 day moving average price of $148.80 and a 200-day moving average price of $153.44. Repligen Co. has a twelve month low of $110.45 and a twelve month high of $211.13. The stock has a market capitalization of $8.17 billion, a price-to-earnings ratio of 583.74, a PEG ratio of 4.23 and a beta of 0.94.

Repligen (NASDAQ:RGEN) last announced its earnings results on Tuesday, July 30th. The biotechnology company reported $0.33 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.33. The company had revenue of $154.07 million during the quarter, compared to analyst estimates of $154.11 million. Repligen had a negative net margin of 0.32% and a positive return on equity of 3.36%. The firm’s quarterly revenue was down 3.2% compared to the same quarter last year. During the same period in the previous year, the business posted $0.53 earnings per share. Equities research analysts forecast that Repligen Co. will post 1.45 earnings per share for the current year.

Insider Activity at Repligen

In related news, VP Ralf Kuriyel sold 4,465 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $165.67, for a total transaction of $739,716.55. Following the completion of the sale, the vice president now directly owns 19,261 shares in the company, valued at $3,190,969.87. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Repligen news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the transaction, the director now directly owns 139,840 shares in the company, valued at $20,328,540.80. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, VP Ralf Kuriyel sold 4,465 shares of the company’s stock in a transaction on Thursday, August 1st. The stock was sold at an average price of $165.67, for a total transaction of $739,716.55. Following the transaction, the vice president now owns 19,261 shares of the company’s stock, valued at approximately $3,190,969.87. The disclosure for this sale can be found here. 1.20% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on RGEN shares. UBS Group cut their target price on shares of Repligen from $205.00 to $185.00 and set a “buy” rating on the stock in a research note on Wednesday, July 31st. Royal Bank of Canada reissued an “outperform” rating and set a $205.00 price target on shares of Repligen in a research report on Thursday. Deutsche Bank Aktiengesellschaft raised shares of Repligen from a “hold” rating to a “buy” rating and lowered their price target for the company from $180.00 to $155.00 in a research report on Wednesday, June 26th. JPMorgan Chase & Co. lifted their price target on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Benchmark reaffirmed a “hold” rating on shares of Repligen in a report on Monday, August 5th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $190.25.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.